Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
Date:4/27/2011

ghts on general corporate matters.

The closing of the offering is expected to occur on May 2, 2011, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the shares of Series 12 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC").  A prospectus supplement under Rule 424 of the Securities Act of 1933, as amended, relating to the offering will be filed with the SEC.  Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.  This press release does not constitute an offer to sell or a solicitation of an offer to buy the Series 12 Preferred Stock or warrants (or the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants).  No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the purchase and sale of the Series 12 Preferred Stock and related warrants might not be consummated, investors might not exercise their
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded ... pioneer in the field of establishing recovery community organizations. ... and when he retired, he set out to answer a ... , 1. Where are the people in ... , 2. Can the recovery community be organized to advocate ...
(Date:10/25/2014)... 25, 2014 Homeowners that are wondering ... bad’ need wonder no more. Clean Crawls gives ... watch out for when it comes to insulation in ... the article released by Clean Crawls, can cause problems ... any insulation that has deteriorated, become damp, or been ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... By Randy Dotinga ... -- As more genetic tests are developed that spot increased ... would be more proactive about getting screened. But a ... does not change behavior: People who found out their genes ... than people with average risk to get screened. "It ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 ... staffing company, is happy to announce that our ... to Staffing Industry Analysts’ Staffing 100 for 2014. ... the “100 most influential people in the staffing ... Medical Solutions, the 13th-largest healthcare staffing company in ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... take medication to manage their symptoms of attention deficit ... ADHD - partially because the process can be so ... to simplify things with expert explanations of popular ADD ... YORK, May 27 ADDitude magazine, the ...
... 27, 2009 The Translational Genomics Research Institute (TGen) ... million to research pancreatic cancer, Stand Up to Cancer ... Physician-In-Chief, and Dr. Craig B. Thompson, Director of the ... pancreatic cancer "Dream Team, which will lead a three-year ...
... May 27 PRA International, a leading Clinical ... Center in its Sao Paulo, Brazil office. Drug Safety ... Risk Management unit. They are staffed with drug safety ... Adverse Drug Reaction management. Furthermore, our drug safety ...
... The Providence Service Corporation (Nasdaq: PRSC ... the proxy statement filed last week by the Avalon ... that the Avalon Group,s proxy statement contains numerous false ... necessary for it to correct the public record with ...
... include worries about family,s reaction, study finds , , WEDNESDAY, ... reaction to their depression is a major reason why ... In the study, which included 368 teens and one ... teens had been diagnosed with depression. The teens and ...
... CLINTON, N.J., May 27 The Sage Group, a ... that HemispherX Biopharma has expanded the mandate for The ... partnering efforts related to Ampligen (an experimental immunotherapeutic) for ... to Ampligen,s use to increase the effectiveness of preventative ...
Cached Medicine News:Health News:ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 3Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 4Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 5Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 2Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 3Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 2Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 3Health News:Stigma Keeps Teens From Depression Treatment 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 3Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 4
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... Freezing Stages fit easily onto most microtomes. ... need only the AC supply and a trickle ... starts immediately and can be maintained indefinitely. ... temperatures can be set for different kinds of ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
Medicine Products: